Last reviewed · How we verify
Sodium Ferric Gluconate Complex in Sucrose.
Sodium ferric gluconate complex in sucrose injection replenishes iron, essential for hemoglobin synthesis and oxygen transport.
At a glance
| Generic name | Sodium Ferric Gluconate Complex in Sucrose. |
|---|---|
| Sponsor | Watson Pharmaceuticals |
| Drug class | Parenteral Iron Replacement [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
This drug works by providing iron to the body, which is crucial for making hemoglobin, the protein in red blood cells that carries oxygen. Iron is also important for various metabolic and enzymatic processes.
Approved indications
Common side effects
- Nausea, vomiting and/or diarrhea
- Injection site reaction
- Hypotension
- Cramps
- Dizziness
- Hypertension
- Dyspnea
- Abnormal erythrocytes
- Chest pain
- Pain
- Leg cramps
- Headache
Serious adverse events
- Myocardial infarction
- Pulmonary edema
- Syncope
- Pneumonia
- Sepsis
- Angina pectoris
- Thrombosis
- Melena
- Decreased level of consciousness
- Carcinoma
Key clinical trials
- Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment (PHASE2)
- Comparing the Efficacy of Different Iron Formulations: Sucrosomal Ferric Pyrophosphate, SunActive®Fe and Intravenous Ferric Gluconate (NA)
- Study of the Efficacy of Two Doses of Ferrlecit in the Treatment of Iron Deficiency in Pediatric Hemodialysis Patients (PHASE4)
- Effect of Two Iron Preparations on Protein in the Urine (PHASE4)
- Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients (PHASE4)
- Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic Agents (PHASE4)
- Comparison Between Effects of Two Iron Preparations on Protein in the Urine (PHASE1)
- Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: